| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
|
Medicine details |
|
| Medicine name | dapagliflozin (Forxiga®) |
| Formulation | oral |
| Reference number | 4258 |
| Indication | Treatment of chronic heart failure, with preserved ejection fraction |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | |